Drupal-Biblio17<style face="normal" font="default" size="100%">The non-genotoxic activator of the p53 pathway Nutlin-3 shifts the balance between E2F7 and E2F1 transcription factors in leukemic cells.</style>Drupal-Biblio17<style face="normal" font="default" size="100%">Activation of the p53 pathway induces α-smooth muscle actin expression in both myeloid leukemic cells and normal macrophages.</style>Drupal-Biblio17<style face="normal" font="default" size="100%">Endothelial cells obtained from patients affected by chronic venous disease exhibit a pro-inflammatory phenotype.</style>Drupal-Biblio17<style face="normal" font="default" size="100%">Hydrogen sulfide down-regulates the expression and release of osteoprotegerin (OPG) by vascular endothelial cells.</style>Drupal-Biblio17<style face="normal" font="default" size="100%">Nutlin-3 differentially modulates miRNA34a and miRNA181 versus miR26a and miR155 in p53 proficient and p53 deficient B chronic lymphocytic leukemia (B-CLL) samples.</style>Drupal-Biblio17<style face="normal" font="default" size="100%">SOCS1 is significantly up-regulated in Nutlin-3-treated p53wild-type B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155.</style>Drupal-Biblio17<style face="normal" font="default" size="100%">The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status.</style>Drupal-Biblio17<style face="normal" font="default" size="100%">miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells.</style>Drupal-Biblio17<style face="normal" font="default" size="100%">Trail down-regulates the release of osteoprotegerin (OPG) by primary stromal cells.</style>Drupal-Biblio17<style face="normal" font="default" size="100%">Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes.</style>